Q-omics provides the consensus-scored NACA2 profile across patient tissues and cancer cell-line models. NACA2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NACA2 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, NACA2 RNA expression shows 10,065 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight LIHC, COAD, and READ as cancer lineages where NACA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NACA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NACA2 survival associations across molecular data types. NACA2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NACA2 RNA expression–survival associations across cancer types. High NACA2 expression shows unfavorable associations in LIHC, LUAD, KICH and ACC, but favorable associations in SKCM and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NACA2 RNA expression.
This table summarizes NACA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NACA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NACA2 shows lower tumor expression in BRCA and higher tumor expression in COAD, KIRC, THCA, LIHC and LUSC. The COAD box plot shows higher NACA2 RNA expression in tumor versus normal tissue (log2 FC = +1.899, t-test p < 0.001).
This table shows molecular features associated with NACA2 in patient tissues and cancer cell lines. In patient samples, NACA2 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set. In cancer cell lines, NACA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
